4th Quarter - Report
TODD STRATEGY GROUP for BIOGEN, INC.
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. H.R.5376 - Inflation Reduction Act of 2022.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | — |
| JEFF LUCAS | — |
| DANIEL M TODD | — |
Medicare/Medicaid MMM
Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Issues regarding coverage, coding, and reimbursement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| JEFF LUCAS | Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon |
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.